Happy Monday Zingernation! I try my best to stay in shape. But hey, sometimes I like to be lazy too. That’s why I’ll always take the elevator up, but you could maybe convince me to take the stairs on the way down.

Stocks, however? They tend to do the exact opposite. Nvidia’s shares have been steadily climbing a staircase all year, eclipsing $950 a share last week. But the stock has been on an elevator heading for the ground floor since, shedding more than $100 a share in less than a couple of trading days.

Before we dive in, check out today’s partner who’s revolutionizing the way we treat colon cancer.

And, looking to learn more about private and public real estate investing? Subscribe to our weekly real estate newsletter delivered every Friday. All it takes is one click.

MARKET SNAPSHOT

Last Week: The market hung around all-time highs, but a sell-off toward the end of the week brought every major index in the red. Let’s see if we can turn it around this week!

On Our Radar: Not a lot planned today, but tomorrow will be a big day for the Street with CPI numbers to be released at 8:30 am ET. Today’s price action could show us how investors are feeling ahead of the report.

TOP STORY

Reddit Eyes Mega IPO, Aiming To Raise $748 Million

Briefly: Well, r/WallStreetBets is going to have a field day with this one. Popular social media platform, Reddit Inc., and its investors are reportedly targeting $748 million in an upcoming initial public offering on March 20. This could rank among the year's largest IPOs.

The Details: As Bloomberg reported on Thursday, Reddit plans to sell 22 million shares, each priced between $31 and $34. This move is speculated to value the company at a hefty $6.5 billion.

Early Birds: Approximately 1.76 million shares in the IPO will be set aside for Reddit's early users and moderators. These shares will not be subject to a lockup period, allowing owners to sell them on the opening day of trading, as per Reddit's filings with the SEC.

A Bumpy Road: The journey to listing has been a long one for Reddit, initially filing back in 2021. Despite the market's ups and downs and the hurdles of the global pandemic, the company's IPO is set to make a splash this year.

Read On: Check out the full scoop here.

PRESENTED BY ELICIO THERAPEUTICS

How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030

Elicio Therapeutics is at the forefront of cancer care with its AMP platform, transforming the landscape with cutting-edge immunotherapies. These innovations are designed not just to treat, but to strategically target and dismantle the very mutations that propel pancreatic and colon cancers. 

The company's leading candidate, ELI-002, embodies this approach, aiming to deliver accessible, non-customized vaccines that promise a new dawn for cancer treatment efficacy and availability.

Though further studies are needed to confirm its efficacy, the shot could improve survival for colon cancer, expected to be the number one cause of cancer deaths for people between 20-49 years of age by 2030, and pancreatic cancer, which has just a 12% survival rate after five years. 

There’s more, click here to keep reading.

FIVE ZINGERS

Suit Up: We talked about Nvidia’s weakness the past couple of days… and now the company’s getting hit with a copyright lawsuit.

A Tale Of Two Currencies: Digital gold (Bitcoin) and old-fashioned gold have both been super hot in 2024. So which one is the better buy?

Ride The Wave: It’s been steady sailing for cruise line stocks this year. Here’s why one analyst expects the strength to continue.

Opportunity Awaits: Needless to say, Cathie Wood is bullish on the future of robotics and AI. Here are her top plays for what she estimates is a $28 trillion opportunity.

On A Budget: Many companies are slashing the prices of electric vehicles, trying to make them more attractive to customers. Chevy’s Blazer is the latest to hit the clearance rack.

ONE FOR THE ROAD

Apple's Now-Defunct Car's Design Would Have 'Wowed Consumers,' Says Gurman

Basically: Well, we’ll always wonder “what could have been.” The demise of Apple, Inc.’s self-driving car has spawned tales about what went wrong. On Sunday, Bloomberg’s Mark Gurman shed some insights into what this hypothetical car would have looked like.

A Brief History: In 2014 when Apple began planning to diversify its revenue stream beyond the iPhone, it zeroed in on an electric vehicle, said Gurman in the latest installment of his weekly “Power On” newsletter. It was a perfect opportunity to get into a “category ripe for disruption that could be transformed with a smartly packaged combination of hardware, software, and services,” he said.

Quoted: “The company could design the coolest-looking car on the road, develop its own underlying operating system, and sell services on top of it — like self-driving features, Apple Music and TV+ video streaming,” said Gurman.

Road Blocks: Indecision, disagreement, technological challenges, and the “cold hard realities” of the auto sector all played a role in the failure of the project. According to Gurman, it’s a “massive disappointment that will alter the course of the company's history, perhaps for decades to come.”

What Next: Check out the full story here.

PRESENTED BY ELICIO THERAPEUTICS

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

An estimated 609,820 people will die of cancer in the United States this year. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease. 

With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. 

ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene.

Click here to learn more and see what’s in store for Elicio Therapeutics in 2024.